RESI Panel Announcement: Preclinical & Phase I Investors, Investing Early in Novel Therapeutics

3 Sep

By Lucy Parkinson, Senior Research Manager, LSN

If you’re developing a biotech asset and you’re raising funds in order to complete pre-IND studies, or to embark on your first human clinical trial, this panel will provide an opportunity to hear from investors who focus on companies at this challenging stage of the development process.

Moderated by Steven Gullans, Managing Director, Excel Venture Management, this panel features:

These investors will offer their insights on the challenge of assessing a biotech opportunity prior to attaining human proof of concept data. What factors do they consider indicative of future success? Which fields of technology are the most promising for early-stage biotech investment today? How do you demonstrate the value of a new breakthrough product to a potential investor? We’ll look forward to hearing the panel’s insights on these and other vital questions faced by Preclinical and Phase I biotechs.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: